#Mirataz

Kindred Biosciences’ Mirataz commercially available in U.S.

May 9, 2018

Update: this product is now commercially available in the U.S. Kindred Biosciences Inc. has received approval from the U.S. Food & Drug Administration for Mirataz (mirtazapine transdermal ointment) for the management of weight loss in cats. Mirtazapine, which blocks specific serotonin and histamine receptors that play a role in appetite and nausea, demonstrated a 3.9 percent increase in body weight in cats with unintended weight loss in as little as 14 days, according to San …
COVID-19
Pets unlikely to pass COVID-19 to humans, other animals
Animal respiratory, GI insurance claims remain consistent in face of COVID-19
COVID-19 myths debunked in webinar
Stay alert of possible ivermectin misuse amid pandemic, FDA warns
K-State licenses technology for coronavirus, norovirus compounds